Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7842461 | 1.00 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL5548155 | 1.00 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL5220048 | 0.91 | ATM (0.45) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL31232348 | 0.91 | ATM (0.45) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL31048296 | 0.91 | ATM (0.45) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL10080538 | 0.89 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL3756852 | 0.89 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL31122917 | 0.89 | ATM (0.46) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL30096598 | 0.89 | ATM (0.43) | ATMPPARAPPARGCTSKCTSS | |
| SCHEMBL28535602 | 0.89 | ATM (0.43) | ATMPPARAPPARGCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | ATM 2213/4885PPARA 455/4885PPARG 1675/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | ATM 2213/4885PPARA 455/4885PPARG 1675/4885 |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | ATM 1382/4885PPARA 1321/4885PPARG 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.